In the current cohort of BC patients, most of whom had not received prior aromatase inhibitor therapy, CCNE1 expression was not associated with decreased PFS, although a trend toward shorter PFS was seen in patients expressing higher CCNE1 and CCNE2 levels (Additional file 6: Fig. S4a, 4b). The gene discussed is CYP19A1; the disease is breast cancer.